SIRPA and neoplasm: Although blocking the interaction between CD47 on tumor cells and SIRPα on the host macrophages and DCs induces antitumor immune responses, simultaneous interruption of the TSP1-CD47 signaling in tumor stromal cells, such as endothelial cells, may potentially facilitate tumor progression.